Detalhe da pesquisa
1.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
N Engl J Med
; 384(19): 1800-1809, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33979488
2.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Am J Respir Crit Care Med
; 208(1): 13-24, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015033
3.
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
Clin Exp Allergy
; 53(4): 417-428, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507576
4.
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
Ann Allergy Asthma Immunol
; 131(3): 343-348.e2, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37263380
5.
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Ann Allergy Asthma Immunol
; 131(5): 587-597.e3, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37619779
6.
One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
J Asthma
; 60(3): 616-624, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35707873
7.
Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial.
J Allergy Clin Immunol
; 150(4): 830-840, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35537502
8.
Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
Allergol Int
; 72(1): 82-88, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977863
9.
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Allergy
; 77(6): 1786-1796, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913186
10.
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.
Eur Respir J
; 58(6)2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112734
11.
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res
; 21(1): 279, 2020 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087119
12.
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Respir Res
; 21(1): 265, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050900
13.
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Respir Res
; 21(1): 264, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050928
14.
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res
; 21(1): 266, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050934
15.
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
Eur Respir J
; 53(2)2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442714
16.
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
BMC Pulm Med
; 19(1): 129, 2019 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31315668
17.
Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study.
Respir Res
; 17(1): 152, 2016 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27842551
18.
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma.
Ann Allergy Asthma Immunol
; 116(1): 37-42, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26707771
19.
Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma.
Ann Allergy Asthma Immunol
; 127(6): 689-691, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34403803
20.
The effect of obesity on outcomes in mechanically ventilated patients in a medical intensive care unit.
Respiration
; 87(3): 219-26, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24457313